Figure 2.
Correlation between EIF5A2 expression and 5-year patient survival. (A and B) Overall and disease-specific 5-year survival of all melanoma patients, respectively (P=0.001, log-rank test). (C and D) Overall and disease-specific 5-year survival of PM patients (P=0.001 and P<0.001, respectively, log-rank test). (E and F) Overall and disease-specific 5-year survival of thin (⩽2 mm) melanoma patients (P=0.026 and 0.044, respectively, log-rank test).